PMDA-ATC MRCT Seminar 2020

Date: 20-23 January, 2020 Venue: Meeting room 21-24@ PMDA 14F

	DAY 1 20 Januray (Mon)	DAY 2 21 January (Tues)	DAY 3 22 January (Wed)	DAY 4 23 January (Thu)
AM-1	09:30-10:00 Registration 10:00-10:20 Opening ceremony	08:55-09:00 Opening/ Agenda for the Day 09:00-10:30 <session 3=""></session> Points to consider when planning & designing MRCT 6_Points of attention for consultation about MRCT	08:55-09:00 Opening/ Agenda for the Day 09:00-10:30 <session 5=""></session> Consideration for MRCT operation 12_Practical issues and solutions on MRCT operations (investigator's view point)	08:55-09:00 Opening/ Agenda for the Day 09:00-10:30 <session 6=""></session> Regulatory review based on results of GCP inspection 16_How to perform GCP inspection -Role of GCP inspection in review process
	10:20-11:05 1_Histry of drug evaluation using overseas data in Japan (incl. Q&A 15 min)	 From PMDA's experience 7_Case study -Planning and designing MRCT (Q&A 15 min) 	13_Practical issues and solutions on MRCT operations (industry's viewpoint) (Q&A 15 min)	 17_How to consider GCP inspection results from reviewer's perspective 18_Applicant's experiences to undergo GCP inspection (incl. Q&A 10 min. each)
Break	11:05-11:20	10:30-10:45	10:30-10:45	10:30-10:45
AM-2	11:20-12:05 2_Scientific insights about ethnic factors (incl. Q&A 15 min.)	10:45-12:45 8_Case study (Group Discussion) (Wrap up 10 min)	10:45-12:15 14_Case study (Group Discussion) (Wrap up 10 min)	10:45-12:00 19_Case study (Group Discussion)
Lunch	12:05-13:30	12:45-14:15	12:15-13:00	12:00-13:30
PM-1	13:30-16:00 <session 1=""></session> 3_Introduciton of review systems and regulations by participants	14:15-15:45 <session 4=""></session> Points to consider when evaluating results 9_Statistical consideration for MRCT based on the ICH E17 G/L 10_PMDA's experiences to review MRCT results (Q&A 15min)	13:15-14:00 move to site 14:00-17:30 15 _Clinical site tour	13:30-14:20 19_Case study (Group Discussion) -continued- (Wrap up 10 min)
Break	16:00-16:15	15:45-16:00		14:20-14:35
PM-2	16:15-17:25 Session 2> International cooperation and alignment 4_Global Platform for Medical Innovation as an Academic Research Organization 5_Challenges for global cooperation of regulatory agencies (Q&A 15min)	16:00-18:00 11_ Case study (Group Discussion) (Wrap up 10 min)		 14:35-16:05 <session 7=""></session> Post market safety evaluation of approved drug based on MRCT 20_Global standard for Pharmacovigilance 21_Risk management plan based on MRCT -industry perspective 22_Risk management based on MRCT -Regulatory Agency Perspective (Q&A 15min)
	17:25 end of the day	18:00 end of the day	17:30 end of the day	16:20-16:50 Closing ceremony